Cellebrite DI (CLBT) CFO David Barter Sells $136K of Stock

Cellebrite DI Ltd. Chief Financial Officer David Barter sold 12,134 shares of the company on October 16, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the transaction was executed at a price of $11.21 per share, totaling approximately $136,069.

CLBT Cellebrite DI Ltd.

$11.03 ▼ -38.17% year to date

1M 3M YTD

Daily close · Oct 16, 2026

Inside David Barter's Cellebrite Trade

The Chief Financial Officer's sale reduced his direct stock ownership by about 3.63%. Following the transaction, Barter retains 322,085 shares of the software provider. This trade was not executed under a pre-arranged Rule 10b5-1 trading plan.

Other Institutional Activity in Cellebrite

Other institutional investors adjusted their holdings in Cellebrite ahead of the filing period. True Wind Capital Management, L.P. kept its stake steady at 13,861,007 shares worth about $152.9 million. Voss Capital, LP grew its holdings by 1,766,689 shares, ending with 11,441,874 shares worth about $126.2 million. Pertento Partners LLP grew its holdings by 1,342,472 shares, ending with 8,004,867 shares worth about $88.3 million. Phoenix Financial Ltd. grew its holdings by 1,999,933 shares, ending with 6,181,269 shares worth about $68.2 million. Nine Ten Capital Management LLC grew its holdings by 682,922 shares, ending with 4,126,808 shares worth about $45.5 million.

Cellebrite DI Ltd. Stock Down 3.1%

Cellebrite shares recently traded around $11.03 as of October 19, 2026. The stock sits below its 50-day moving average of $11.71 and below its 200-day moving average of $13.72. Shares have traded between a 52-week low of $9.58 and a 52-week high of $19.98.

Recent Earnings

The software company generated $514.3 million in trailing-twelve-month revenue with a net profit margin of 11.4%. Its trailing P/E ratio stands at 48.0, while the forward P/E is 16.9. The company's next quarterly financial report is scheduled for November 11, 2026.

Insider Buying and Selling at Cellebrite DI Ltd.

Other insiders also completed transactions prior to this filing. On August 21, 2026, officer David Nicholas Gee sold 2,198 shares for about $24,709. On the same day, officer Marcus H Jewell sold 12,562 shares for about $141,217. A few days later on August 24, 2026, David Nicholas Gee sold another 4,323 shares for about $49,111. Thomas E Hogan sold 25,299 shares on August 25, 2026, for about $285,712.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock in August and September 2026. On August 14, 2026, Lake Street maintained its Buy rating with a $15.00 target. On the same date, JP Morgan maintained an Overweight rating with a $16.00 target, DA Davidson maintained a Buy rating with a $15.00 target, and Needham maintained a Buy rating with a $12.50 target. DA Davidson later maintained a Buy rating with a $15.00 target on September 15, 2026. The stock carries a consensus strong buy rating with an average price target of $15.36 across 7 analyst opinions.

About Cellebrite

Cellebrite builds digital intelligence software and investigative tools for law enforcement agencies and enterprise clients. Its technology helps organizations manage legally sanctioned digital investigations, collect evidence, and analyze data across multiple jurisdictions. The company's operational performance remains closely watched by institutional investors as law enforcement digital forensics demand evolves.

Bottom Line

CFO David Barter's recent sale trims his personal holdings by a small margin while broader institutional backing remains active. Investors will look toward the upcoming financial results on November 11, 2026, for further insight into the company's revenue growth and profitability.